Ribomic, Inc. (4591) Press Release
[Delayed]RIBOMIC Announces No Safety Concerns After Three Months of 1mg/kg Weekly Treatment with Umedaptanib Pegol in Achondroplasia Phase2 Study
Earlier from Ribomic
- RIBOMIC Announces Completion of Clinical Trial Site Establishment for the Phase 3 Clinical Trial of Umedaptanib Pegol in Achondroplasia
- Summary of Non-Consolidated Financial Results for the Three Months Ended June 30 2026(Based on Japanese GAAP)
- RIBOMIC Announces First Patient In (FPI) in the Phase 3 Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia
- RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older